PharmTech Drug Digest 11.20
News|Articles|January 23, 2026

Pharmaceutical Technology

  • Pharmaceutical Technology January February 2026
  • Volume 50
  • Issue 01
  • Pages: 4

Bold vision. Grand scale.

Today, we’re taking our brand to the next level so we can strengthen our commitment to scientists, innovators, and C-suite leaders who trust us for science-driven insights for faster and smarter manufacturing of safe, effective, successful therapies.

Through every era of modern pharma, PharmTech has been the voice for practical, real-world strategy. We make complex breakthroughs professionally applicable, and we fundamentally drive advanced development and manufacturing every day.

Today, we’re taking our brand to the next level so we can strengthen our commitment to scientists, innovators, and C-suite leaders who trust us for science-driven insights for faster and smarter manufacturing of safe, effective, successful therapies.

We’re magnifying engagement.

We earned our place as the market leader by creating uniquely expert content and engaging media platforms. Through 2025, we developed a bold, new look and content strategy. The design is incredible and we’re excited for you to experience it.

We’re personifying expertise.

Our content authority comes from alignment with top experts across the field. By staying united with key opinion leaders in pharma, we can deliver impartial and objective insights. Our new media strategy elevates these stars, giving them the spotlight they deserve.

We’re embracing who we are.

For more than 25 years, the official name has been Pharmaceutical Technology. But we know ourselves as PharmTech. You do, too. Everyone does. Why? It’s precise. Gets right to the point. It’s picture-perfect for our approach to the industry.

We’re acting like market leaders.

Call us humble. We earned #1, and we focus on excellence. But this industry is defined by competition. So, we’re putting on the gloves as the comprehensive leader in engagement with key decision-makers in pharma and biopharma. Reach, quality, versatility—always.

Mike Hennessy Jr
President and CEO
MJH Life Sciences®


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.